Summary
The provided FDA label excerpts address thyroid C-cell tumor risk/contraindications, but the AI response claims detailed information about expiration dates, potency loss, sterility/stability, and patient guidance that are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
An expiration date on a semaglutide pen or vial is the manufacturer’s cutoff for when the medication is expected to still be effective and safe under recommended storage conditions.
No supported label language provided in the supplied excerpts regarding expiration-date meaning, effectiveness, or safety expectations.
After the expiration date, semaglutide may lose potency.
No supported label language provided in the supplied excerpts about potency loss after expiration.
After the expiration date, sterility assurance for semaglutide can’t be guaranteed.
No supported label language provided in the supplied excerpts regarding sterility assurances after expiration.
Generally, semaglutide should not be used after its expiration date.
No supported label language provided in the supplied excerpts stating whether semaglutide should or should not be used after expiration.
Using semaglutide after its expiration date is not recommended because the manufacturer has not validated its quality beyond that point.
No supported label language provided in the supplied excerpts regarding manufacturer validation/quality beyond expiration.
After the expiration date, semaglutide potency may decline.
No supported label language provided in the supplied excerpts about potency decline after expiration.
Using semaglutide past expiration can result in reduced effectiveness, with blood sugar and weight-control results possibly being worse.
No supported label language provided in the supplied excerpts linking expiration to reduced effectiveness or effects on blood glucose/weight outcomes.
Using semaglutide past expiration may create potential safety concerns if the product’s sterility or stability has been compromised.
No supported label language provided in the supplied excerpts addressing safety concerns related to sterility/stability after expiration.
The likelihood of issues from using semaglutide past expiration depends on how the product was stored, including whether it stayed refrigerated and protected from temperature swings.
No supported label language provided in the supplied excerpts regarding temperature/storage effects on expired product risks.
There is no reliable way for a patient to confirm semaglutide potency after expiration.
No supported label language provided in the supplied excerpts about patient ability to confirm potency after expiration.
Once the printed expiration date has passed, semaglutide should be treated as expired and replaced rather than reused.
No supported label language provided in the supplied excerpts directing replacement/reuse guidance after expiration.
There aren’t standard, patient-level exceptions that make it appropriate to use semaglutide after its expiration date.
No supported label language provided in the supplied excerpts stating the existence or non-existence of exceptions for using after expiration.
Contradictions
Low
AI Statement
Risk of thyroid C-cell tumors / MTC (medullary thyroid carcinoma) (WARNING/contraindication context)
Label Reference
Supplied label excerpt under 5.1 indicates rodent thyroid C-cell tumor risk with unknown human relevance and that Ozempic/Wegovy are contraindicated in patients with personal/family history of MTC or MEN 2.
Important Omissions
No supported on-label discussion (from the provided excerpts) connecting expiration-date handling/expiration guidance to semaglutide effectiveness, safety, sterility/stability, potency, storage conditions, patient verification, or patient exception criteria.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The AI response makes multiple patient-facing claims about expiration-date use, potency, sterility, and safety concerns without support from the supplied prescribing-information excerpts; this could lead to inappropriate decisions about medication use or disposal.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Expiration-date and post-expiration guidance claims are not supported by the provided FDA label text.
Suggested Improvement
Limit the response to on-label content present in the supplied label excerpts (thyroid C-cell tumor warning, contraindications for MTC/MEN 2, and counseling/monitoring statements). If expiration guidance is needed, provide and evaluate the specific label sections covering storage, handling, and expiration.